2000
Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks
Roberts J, Shibata S, Spicer D, McLeod H, Tombes M, Kyle B, Carroll M, Sheedy B, Collier M, Pithavala Y, Paradiso L, Clendeninn N. Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemotherapy And Pharmacology 2000, 45: 423-427. PMID: 10803927, DOI: 10.1007/s002800051012.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityPhase II doseCumulative toxicityAdvanced malignanciesIntravenous bolusAUC0-24Pharmacodynamic factorsFolate supplementationPlasma concentrationsIntermediate dosePharmacokinetic analysisDose levelsELISA assaysDosePhase IAG2034Progressive increaseGARFT inhibitorToxicityWeeksInhibitorsMucositisThrombocytopeniaDiarrheaHyperbilirubinemia
1989
Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer.
Colletti RB, Roberts JD, Devlin JT, Copeland KC. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Research 1989, 49: 1882-4. PMID: 2924327.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor IBreast cancer patientsGrowth factor ICancer patientsPlasma IGFBreast cancerAmbulatory breast cancer patientsPlasma insulin-like growth factor IFactor IPlasma IGF-I concentrationsPlasma IGF-I levelsAntiestrogen agent tamoxifenRecent weight lossIGF-I levelsEffect of tamoxifenIGF-I concentrationsHuman breast cancer cellsSuppression of IGFGrowth hormone-dependent peptideBreast cancer cellsMetastatic diseasePlasma concentrationsPatientsTamoxifenNutritional status